Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
More than half a century after their discovery, benzodiazepines (BDZs) still represent one of the largest and most widely prescribed groups of psychotropic compounds, not only in clinical psychiatry but also in the entire medical field. Over the last two decades, however, there has been an increased focus on the development of antidepressants and antipsychotics on the part of the pharmaceutical industry, clinicians, and researchers, with a reduced interest in BDZs, in spite of their widespread clinical use. As a consequence, many psychiatric residents, medical students, nurses, and other mental health professionals might receive poor academic teaching and training regarding these agents, and have the false impression that BDZs represent an outdated chapter in clinical psychopharmacology. However, recent advances in the field, including findings concerning epidemiology, addiction risk, and drug interactions, as well as the introduction of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition with related diagnostic changes, strongly encourage an updated appraisal of the use of BDZs in clinical practice. During a recent thematic event convened with the aim of approaching this topic in a critical manner, a group of young Italian psychiatrists attempted to highlight possible flaws in current teaching pathways, identify the main clinical pros and cons regarding current use of BDZs in clinical practice, and provide an updated overview of their use across specific clinical areas and patient populations. The main results are presented and discussed in this review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The American Geriatrics Society 2012 Beers Criteria Update Expert Panel (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.03923.x · Cited by 2,578
Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults
Schutte-Rodin, S., Broch, L., Buysse, D., Dorsey, C., & Sateia, M. (2008) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27286 · Cited by 1,943
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Development of a rational scale to assess the harm of drugs of potential misuse
Nutt, D., King, L. A., Saulsbury, W., & Blakemore, C. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60464-4 · Cited by 1,302 · cited 1×
“161 Dose, route of administration, coadmin-istration with other drugs, context of use, and expectations are associated with substance dependence.”
Behavioral and Pharmacological Therapies for Late-Life Insomnia: A Randomized Controlled Trial
Morin, C. M., Colecchi, C., Stone, J., Sood, R., & Brink, D. (1999) · JAMA · doi:10.1001/jama.281.11.991 · Cited by 1,095 · cited 1×
“63 With respect to sleep microarchitecture, BDZs are associated with a significant decrease in electroencephalographic arousals, as well as a reduction of slow frequencies and an increase in fast frequencies on the electroencephalogram.”
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090 · cited 1×
“17 Adjunctive lorazepam in treatment-resistant OCD patients did not result in any beneficial effect over placebo.”
Benzodiazepine Use in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1763 · Cited by 786
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676 · cited 5×
“25,49 The limited data on relapse prevention, potential withdrawal difficulties, and the restricted spectrum of action of BDZs in the generalized subtype of SAD limit their use in this condition.”
InfluentialAnxiety and Depression in Later Life: Co-Occurrence and Communality of Risk Factors
Beekman, A. T. F., de Beurs, E., van Balkom, A. J. L. M., Deeg, D. J. H., van Dyck, R., & van Tilburg, W. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.89 · Cited by 669
Wilson, S., Nutt, D., Alford, C., Argyropoulos, S., Baldwin, D., Bateson, A., Britton, T., Crowe, C., Dijk, D.-J., Espie, C., et al. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110379307 · Cited by 634
Stunkard, A. J., Grace, W. J., & Wolff, H. G. (1955) · The American Journal of Medicine · doi:10.1016/0002-9343(55)90276-x · Cited by 612
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia
Lunn, M. P., Hughes, R. A., & Wiffen, P. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007115.pub3 · Cited by 565 · cited 1×
“51 In psychosomatic disorders, first-line treatments include duloxetine, milnacipran, tryciclic antidepressants and pregabalin, 50,52 while BDZs (alprazolam and bromazepam) are not usually recommended as first-line treatment.”
Cognitive Effects of Long-Term Benzodiazepine Use: A Meta-Analysis
Barker, M. J., Greenwood, K. M., Jackson, M., & Crowe, S. F. (2004) · CNS Drugs · doi:10.2165/00023210-200418010-00004 · Cited by 552
Lam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431 · cited 3×
“111 The Canadian Network for Mood and Anxiety Treatments and the International Society for Bipolar Disorders guidelines 112 advocate the use of adjunctive BDZs in patients who refuse oral medications for agitation, but not as monotherapy.”
Oldham, J. M. (2005) · Focus · doi:10.1176/foc.3.3.396 · Cited by 429
Bandelow, B., Sher, L., Bunevicius, R., Hollander, E., Kasper, S., Zohar, J., Möller, H.-J., WFSBP Task Force on Mental Disorders in Primary Care, & WFSBP Task Force on Anxiety Disorders, O. A. P. (2012) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2012.667114 · Cited by 428
Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant
Iqbal, M. M., Sobhan, T., & Ryals, T. (2002) · Psychiatric Services · doi:10.1176/appi.ps.53.1.39 · Cited by 427 · cited 1×
“Neonatal withdrawal reactions have been described, 121 so attention should be paid to women taking BDZs in the days immediately before delivery.”
FAVA, M., ALPERT, J. E., CARMIN, C. N., WISNIEWSKI, S. R., TRIVEDI, M. H., BIGGS, M. M., SHORES-WILSON, K., MORGAN, D., SCHWARTZ, T., BALASUBRAMANI, G. K., et al. (2004) · Psychological Medicine · doi:10.1017/s0033291704002612 · Cited by 406
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & WFSBP Task Force On Treatment Guidelines For Bipolar Disorders (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903555881 · Cited by 399 · cited 1×
“111 The Canadian Network for Mood and Anxiety Treatments and the International Society for Bipolar Disorders guidelines 112 advocate the use of adjunctive BDZs in patients who refuse oral medications for agitation, but not as monotherapy.”
Neural bases for addictive properties of benzodiazepines
Tan, K. R., Brown, M., Labouèbe, G., Yvon, C., Creton, C., Fritschy, J.-M., Rudolph, U., & Lüscher, C. (2010) · Nature · doi:10.1038/nature08758 · Cited by 397 · cited 1×
“64 Further, BDZs reduce the instability of non-rapid eye movement sleep and protect against noise-induced perturbation.”
Benzodiazepine harm: how can it be reduced?
Lader, M. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04418.x · Cited by 359
Dolovich, L. R., Addis, A., Vaillancourt, J. M. R., Power, J. D. B., Koren, G., & Einarson, T. R. (1998) · BMJ · doi:10.1136/bmj.317.7162.839 · Cited by 353
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
Anxiety in the eating disorders: Understanding the overlap
Pallister, E., & Waller, G. (2008) · Clinical Psychology Review · doi:10.1016/j.cpr.2007.07.001 · Cited by 315 · cited 1×
“148 However, BDZs are sometimes used in subjects with eating disorders, mostly when a comorbid anxiety disorder is present, 149 or to treat anxiety related to food/body issues, severe insomnia, or excessive physical exercise, although no controlled evidence is available to guide such choices.”
Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis
Barker, M. (2004) · Archives of Clinical Neuropsychology · doi:10.1016/s0887-6177(03)00096-9 · Cited by 307 · cited 1×
“230,231 The same study showed that these impairments persist well beyond cessation of BDZ use.”
Paradoxical reactions to benzodiazepines: literature review and treatment options
Mancuso, C. E., Tanzi, M. G., & Gabay, M. (2004) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.13.1177.38089 · Cited by 298 · cited 2×
“Paradoxical excitement/disinhibition Case reports of paradoxical excitement/disinhibition (increased talkativeness, emotional release, excitement, and excessive movement) and/or violence have been reported, raising many concerns among primary care physicians about whether BDZ use alone can result in disinhibited or im…”
Zanarini, M. C., Frankenburg, F. R., Hennen, J., & Silk, K. R. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0105 · Cited by 285
Epidemiologic and clinical updates on impulse control disorders: a critical review
Dell’Osso, B., Altamura, A. C., Allen, A., Marazziti, D., & Hollander, E. (2006) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-006-0668-0 · Cited by 272
Self-citationBenzodiazepines: Risks and Benefits. A Reconsideration
Baldwin, D. S., Aitchison, K., Bateson, A., Curran, H. V., Davies, S., Leonard, B., Nutt, D. J., Stephens, D. N., & Wilson, S. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113503509 · Cited by 249 · cited 6×
“9 Growing epidemiological evidence links therapeutic use of BDZs to an increased risk of traffic accidents; this implies that tolerance may supervene to therapeutic effects (eg, hypnotic and anxiolytic effects) but not so, or to a definitely lesser extent, to complex perceptual and psychomotor…”
InfluentialBerlim, M. T., & Turecki, G. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.03.009 · Cited by 249 · cited 1×
“92 Despite an increasing variety of choice, BDZs are widely used in clinical practice to improve residual symptoms of depression and/ or anxiety, but their use as add-on treatments in resistant or prolonged depression is only supported by some case reports and open studies.”
Tannenbaum, C., Paquette, A., Hilmer, S., Holroyd-Leduc, J., & Carnahan, R. (2012) · Drugs & Aging · doi:10.1007/bf03262280 · Cited by 241
Dell’osso, B., & Lader, M. (2013) · European Psychiatry · doi:10.1016/j.eurpsy.2011.11.003 · Cited by 210 · cited 2×
“8,9 However, BDZs and related BDZ receptor agonists are the most effective pharmacological treatment for insomnia to date.”
Self-citationAigner, M., Treasure, J., Kaye, W., Kasper, S., & The WFSBP Task Force on Eating Disorders (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.602720 · Cited by 207
Review of pharmacological therapies in fibromyalgia syndrome
Häuser, W., Walitt, B., Fitzcharles, M.-A., & Sommer, C. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4441 · Cited by 188 · cited 2×
“50 However, in this review, the focus is on psychosomatic diseases that have been managed with BDZs.”
Fava, M., Rush, A. J., Alpert, J. E., Carmin, C. N., Balasubramani, G., Wisniewski, S. R., Trivedi, M. H., Biggs, M. M., & Shores-Wilson, K. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605101304 · Cited by 183 · cited 1×
“93 In particular, recent evidence has been provided by the STAR*D (Sequenced Treatment Alternatives to Relieve Depression) study, 94,95 in which researchers found that patients affected by anxious depression have a slow response rate to antidepressive treatment.”
Offidani, E., Guidi, J., Tomba, E., & Fava, G. A. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000353198 · Cited by 166
Antidepressants plus benzodiazepines for major depression
Furukawa, T. A., Streiner, D., Young, L. T., & Kinoshita, Y. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001026 · Cited by 161
Fracture Risk From Psychotropic Medications: A Population-Based Analysis
Bolton, J. M., Metge, C., Lix, L., Prior, H., Sareen, J., & Leslie, W. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31817d5943 · Cited by 158 · cited 1×
“with all psychotropic medications (eg, with all drugs that may cause postural hypotension) and is associated, for BDZs, with higher doses.(241) Therefore, BDZs should be cautiously used in elderly patients, and patients and relatives should be warned appropriately about the risks of use of these drugs.”
Usage of benzodiazepines: A review
Donoghue, J., & Lader, M. (2010) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651500903447810 · Cited by 156 · cited 1×
“54 The treatment of sleep disorders, and insomnia in particular, is complex, and depends on numerous patient-related factors, including age, likely duration of treatment, and psychiatric and medical comorbidity.”
Nielsen, S., Lintzeris, N., Bruno, R., Campbell, G., Larance, B., Hall, W., Hoban, B., Cohen, M. L., & Degenhardt, L. (2015) · Pain Medicine · doi:10.1111/pme.12594 · Cited by 131
Clomipramine, Clonazepam, and Clonidine Treatment of Obsessive-Compulsive Disorder
HEWLETT, W. A., VINOGRADOV, S., & AGRAS, W. S. (1992) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199212000-00008 · Cited by 129 · cited 1×
“The results of double-blind studies with clonazepam are controversial, 14,15 and an open trial with alprazolam 16 did not support the efficacy of BDZs for OCD or anxiety symptoms.”
Mugunthan, K., McGuire, T., & Glasziou, P. (2011) · British Journal of General Practice · doi:10.3399/bjgp11x593857 · Cited by 123 · cited 2×
“13 In order to critically revise the current state of the art regarding use of BDZs in clinical practice from the perspective of a group of young academic clinicians, the present review sought to: provide an updated overview of BDZ use in various psychiatric disorders and populations; highlight the…”
Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview
Bellantuono, C., Tofani, S., Di Sciascio, G., & Santone, G. (2013) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2012.09.003 · Cited by 122 · cited 1×
“A recent critical overview concluded that data published in the last 10 years do not indicate an absolute contraindication to prescribing BDZs during the first gestational trimester.(250) Differences in the risk reported for each compound may explain the controversial results.”
Bierman, E. J. M., Comijs, H. C., Gundy, C. M., Sonnenberg, C., Jonker, C., & Beekman, A. T. F. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1811 · Cited by 114
Cates, M. E., Bishop, M. H., Davis, L. L., Lowe, J. S., & Woolley, T. W. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e043 · Cited by 105
The evidence-based pharmacotherapy of social anxiety disorder
Blanco, C., Bragdon, L. B., Schneier, F. R., & Liebowitz, M. R. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000119 · Cited by 99 · cited 1×
“47 Consequently, clonazepam is the only BDZ listed among the evidence-based treatments for SAD by the WFSBP guidelines, 23 despite the limited evidence from controlled studies (category of evidence B).”
A double-blind, placebo-controlled trial of clonazepam in obsessive–compulsive disorder
Hollander, E., Kaplan, A., & Stahl, S. M. (2003) · The World Journal of Biological Psychiatry · doi:10.3109/15622970309167908 · Cited by 97 · cited 1×
“The results of double-blind studies with clonazepam are controversial, 14,15 and an open trial with alprazolam 16 did not support the efficacy of BDZs for OCD or anxiety symptoms.”
The reappraisal of benzodiazepines in the treatment of anxiety and related disorders
Starcevic, V. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.963057 · Cited by 90
Risk of suicide attempts after benzodiazepine and/or antidepressant use
Neutel, C. I., & Patten, S. B. (1997) · Annals of Epidemiology · doi:10.1016/s1047-2797(97)00126-9 · Cited by 88 · cited 1×
“According to Neutel and Patten, 206 the association between BDZ use and attempted suicide was particularly high.”
Benzodiazepine use and aggressive behaviour: a systematic review
Albrecht, B., Staiger, P. K., Hall, K., Miller, P., Best, D., & Lubman, D. I. (2014) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414548902 · Cited by 87 · cited 4×
“sonality traits, including BPD traits, particularly combined with alcohol use, have been correlated with an increased risk of aggressive behavior following BDZ use.(4,136) The APA guidelines suggest use of BDZs, particularly clonazepam, in the treatment of “affect dysregulation” in the presence of anxiety symptoms tha…”
InfluentialFiorillo, A., Luciano, M., Del Vecchio, V., Sampogna, G., Obradors‐Tarragó, C., Maj, M., & on behalf of the ROAMER Consortium (2013) · World Psychiatry · doi:10.1002/wps.20052 · Cited by 74
Self-citationCognitive effects of long-term benzodiazepine use in older adults
Pat McAndrews, M., Weiss, R. T., Sandor, P., Taylor, A., Carlen, P. L., & Shapiro, C. M. (2003) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.453 · Cited by 68 · cited 1×
“88–91 Another area of potential clinical usefulness for BDZs is treatment-resistant depression, generally defined as failure to achieve remission after at least two trials of antidepressant treatment of adequate duration and dose.”
Evidence-based pharmacotherapy of panic disorder: an update
Batelaan, N. M., Van Balkom, A. J. L. M., & Stein, D. J. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000800 · Cited by 67 · cited 1×
“Nonetheless, Batelaan et al 41 reported that alprazolam and clonazepam were efficacious as maintenance treatment for panic disorder.”
Van Ameringen, M., Simpson, W., Patterson, B., Dell’Osso, B., Fineberg, N., Hollander, E., Hranov, L., Hranov, G., Lochner, C., Karamustafalioglu, O., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113517955 · Cited by 65 · cited 1×
“20 This finding highlights the perception of clinicians that BDZs are useful add-on treatments for OCD patients, at least at the start of treatment with a selective serotonin reuptake inhibitor (SSRI).”
Self-citationTreating Nonspecific Anxiety and Anxiety Disorders in Patients With Bipolar Disorder: A Review
Rakofsky, J. J., & Dunlop, B. W. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09r05815gre · Cited by 52
Training and practice of psychotherapy in Europe: results of a survey
FIORILLO, A., LUCIANO, M., GIACCO, D., DEL VECCHIO, V., BALDASS, N., DE VRIENDT, N., THEODORIDES, N., PIIR, P., COURTOIS, A., GERBER, S., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00064.x · Cited by 41 · cited 1×
“12,225 Another critical area that needs to be covered by improved education and training is that of primary care physician education, 226,227 being general practitioners BDZ prescribers as frequently as psychiatrists.”
Self-citationStevens, E. S., Jendrusina, A. A., Sarapas, C., & Behar, E. (2014) · The Wiley Handbook of Anxiety Disorders · doi:10.1002/9781118775349.ch21 · Cited by 9
Cited by
Carmassi, C., Foghi, C., Dell'Oste, V., Cordone, A., Bertelloni, C. A., Bui, E., & Dell'Osso, L. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113312 · Cited by 607
“Efficacious treatments for PTSD and PTSS exist (Lee and Bowles, 2020; Charney et al., 2018; Dell'Osso et al., 2015), and healthcare systems should also focus on prepare to roll out these treatments among HCWs should prevention strategies fail to prevent the development of these conditions.”
Self-citationAcute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Self-citationExamining racial/ethnic differences in patterns of benzodiazepine prescription and misuse
Cook, B., Creedon, T., Wang, Y., Lu, C., Carson, N., Jules, P., Lee, E., & Alegría, M. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.02.011 · Cited by 60
“, 2013; Dell’osso and Lader, 2013; Lader, 2011), and multiple provider guidelines recommend that BZD prescription be limited to a short duration (Ashton, 1994; Dell’Osso et al., 2015).”
BackgroundExperiences with benzodiazepine use, tapering, and discontinuation: an Internet survey
Reid Finlayson, A. J., Macoubrie, J., Huff, C., Foster, D. E., & Martin, P. R. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253221082386 · Cited by 40
Poloni, N., Ielmini, M., Caselli, I., Ceccon, F., Bianchi, L., Isella, C., & Callegari, C. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00626 · Cited by 28
Self-citation
Metadata
- Authors
- Fiorillo, A., Dell'Osso, B., Albert, U., Atti, A. R., Carmassi, C., Carrà, G., Cosci, F., Del Vecchio, V., Di Nicola, M., Ferrari, S., Goracci, A., Iasevoli, F., Luciano, M., Martinotti, G., Nanni, M. G., Nivoli, A., Pinna, F., Poloni, N., Pompili, M., Sampogna, G., Tarricone, I., Tosato, S., & Volpe, U.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2015-07
- Volume
- 11
- Pages
- 1885
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- OpenAlex
- W1604275094
- Cited by
- 67
- References
- 58
- FWCI
- 1.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.